These are preliminary reports that have not been peer-reviewed. They should not be regarded as conclusive, guide clinical practice/health-related behavior, or be reported in news media as established information. For more information, please see our FAQs.
Total Synthesis of the Brevicidine and Laterocidine Family of Lipopeptide Antibiotics
preprintsubmitted on 29.01.2021, 07:48 and posted on 01.02.2021, 06:23 by Karol Al-Ayed, Ross D. Ballantine, Zheng Zhong, Yongxin Li, Stephen Cochrane, Nathaniel Martin
Brevicidine and laterocidine are two recently discovered lipopeptide antibiotics with promising antibacterial activity. Possessing a macrocyclic core, multiple positive charges, and a lipidated N-terminus, these lipopeptides exhibit potent and selective activity against Gram-negative pathogens including polymyxin-resistant isolates. Given the low amounts of brevicidine and laterocidine accessible by fermentation of the producing microorganisms, synthetic routes to these lipopeptides present an attractive alternative. We here report the convenient solid-phase syntheses of both brevicidine and laterocidine and confirm their potent anti-Gram-negative activities.
Addressing Antibiotic Resistance: New Strategies for Overcoming the ESKAPE Pathogens
European Research CouncilFind out more...
Synthesis of novel brevicidine and laterocidine analogues active against multi-drug-resistant Gram-negative bacteria
Engineering and Physical Sciences Research CouncilFind out more...